Michael Pearson is leading the bid by Valeant Pharmaceuticals (VRX) to take over Cephalon (NASDAQ:CEPH), his biggest bet so far on a theory that the drug industry’s traditional growth model - heavy R&D spending - is broken. The surest road to growth, he says, is through acquisitions.